Yüklüyor......
Benefit–risk evaluation: the past, present and future
In the last two decades there has been a shift in the approach to evaluating the benefit–risk (BR) profiles of medicinal products from an unstructured, subjective, and inconsistent, to a more structured and objective, process. This article describes that shift from a historical perspective; the past...
Kaydedildi:
| Yayımlandı: | Ther Adv Drug Saf |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6712756/ https://ncbi.nlm.nih.gov/pubmed/31489173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098619871180 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|